ESOPHAGOGASTRIC
DISEASE ORIENTED GROUP
AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO
DATE SATURDAY, APRIL 30th, 2016
TIME: 13:30 – 15:00 pm

CHAIRS: DR. REBECCA WONG & DR. CHRISTIAN KOLLMANSBERGER

13:30 WELCOME AND INTRODUCTION
DR. R. WONG / DR. C. KOLLMANSBERGER

ACTIVE TRIALS FOR UPDATE/DISCUSSION

13:35 GA.1 (TOP GEAR): A RANDOMIZED PHASE III TRIAL OF PREOPERATIVE CHEMORADIOOTHERAPY VERSUS PREOPERATIVE CHEMOTHERAPY FOR RESECTABLE GASTRIC CANCER
DR. J. RINGASH

APPROVED TRIALS IN DEVELOPMENT

13:50 GA.3 (INTEGRATE II) - A RANDOMIZED PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF REGORAFENIB IN REFRactory ADVANCED OESOPHAGO-GASTRIC CANCER (AOGC)
DR. T. ALCINDOR

CONCEPTS IN DEVELOPMENT

14:10 A SINGLE ARM PHASE II TRIAL OF NEOADJUVANT PEMBROLIZUMAB + CHEMORADIATION (CROSS PROTOCOL) FOR ESOPHAGEAL ADENOCARCINOMA
DR. J. MONZON

14:20 A RANDOMIZED PHASE II TRIAL OF ADJUVANT DURVALUMAB (MEDI4736) FOLLOWING ESOPHAGECTOMY FOR ESOPHAGEAL ADENOCARCINOMA
DR. G. DARLING

14:30 IXO IN FIRST LINE METASTATIC (HER2 -) GASTRIC AND GEJ ADENOCARCINOMA
DR. J. SPRATLIN

14:40 PILOT RCT NEOADJUVANT CT VS CRT IN ESOPHAGUS (POWERRANGER)
DR. G. BUDUHAN

14:50 INTERGROUP TASK FORCE UPDATE
DR. R. WONG & Dr. C. KOLLMANSBERGER

15:00 CLOSING REMARKS